Skip to main content
Log in

Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) in Patients with Gastrointestinal Side Effects: Case Studies

  • Case Report
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 645–63

    Article  PubMed  CAS  Google Scholar 

  2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–5

    Google Scholar 

  3. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290–7

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anita Boswell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boswell, A., Shehata, M. Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) in Patients with Gastrointestinal Side Effects: Case Studies. Drugs 66 (Suppl 2), 19–22 (2006). https://doi.org/10.2165/00003495-200666002-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666002-00006

Keywords

Navigation